Biotechnology company Advaxis Inc (NASDAQ:ADXS) stated on Thursday its net loss of USD66.5m (USD1.29 per share) for the fiscal year ended 31 October 2018.
This marks a rise in earnings when compared with a net loss of USD93.4m (USD2.31 per share) for fiscal 2017.
Revenues of USD6.063m and USD12.03m were generated in fiscal 2018 and fiscal 2017, respectively.
Research and development expenses of USD57.0m were recorded for fiscal 2018, a decline over R&D of USD70.5m for fiscal 2017, primarily attributable to a decrease in laboratory costs, drug manufacturing process validation and drug stability studies.
In fiscal year 2018, the company received the US FDA's allowance for the Investigational New Drug application for ADXS-HOT off-the-shelf neoantigen drug candidate, ADXS-503 for the all types of non-small cell lung cancer; Dosed the first patients in the ADXS-NEO Phase 1 dose-escalation study for several solid tumour types; licensed ADXS-HER2 to OS Therapies for evaluation of pediatric osteosarcoma; as well as presented data from several preclinical and clinical trials with the drug candidates.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study